Market Size
The global myasthenia gravis therapeutics market reached USD 1.64 billion in 2025 and is expected to reach USD 3.48 billion by 2033, growing at a CAGR of 9.6% during the forecast period 2026 to 2033.
Myasthenia gravis is a long-term neuromuscular disease that leads to varying degrees of skeletal muscle weakness. Muscles of the eyes, face and swallowing are the most commonly affected muscles in the body. The weakening of these muscles can result in double vision, drooping eyelids, trouble talking, and trouble walking. Although a rare disease, the prevalence of the disease has increased over the past few decades, as per National Organization for Rare Disorders. As a result, the research and development in understanding the disease and finding a cure have also increased these factors have driven the growth of the market in the forecast period.
Myasthenia Gravis Therapeutics Market Summary
| Metrics | Details |
| CAGR | 9.6% |
| Size Available for Years | 2025-2033 |
| Forecast Period | 2026-2033 |
| Data Availability | Value (US$) |
| Segments Covered | By Type, By Treatment, By End-user and Region |
| Regions Covered | North America, Europe, Asia-Pacific, South America, and Middle East & Africa |
| Fastest Growing Region | Asia-Pacific |
| Largest Region | North America |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, Porter’s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis, and Orthopedic Surgery key Insights. |
For More Insights Request Free Sample
Market Dynamics
The Myasthenia Gravis Therapeutics Market is gaining steady traction driven by the increasing prevalence of autoimmune disorders and growing awareness about early diagnosis and treatment options. Myasthenia gravis, a chronic neuromuscular disease, requires long-term management, which is boosting demand for effective therapeutic solutions such as immunosuppressants, monoclonal antibodies, and cholinesterase inhibitors. Advancements in targeted therapies, particularly biologics and complement inhibitors, are transforming treatment approaches by offering improved efficacy and reduced side effects. Additionally, expanding healthcare infrastructure, rising investment in rare disease research, and supportive regulatory frameworks for orphan drugs are contributing to the market’s growth.
However, the market faces several challenges that may hinder its expansion. High treatment costs, especially for advanced biologics, can limit accessibility for patients in developing regions. The rarity of the disease also poses challenges in conducting large-scale clinical trials and achieving widespread commercialization. Moreover, potential side effects associated with long-term immunosuppressive therapy and limited awareness in certain regions can impact treatment adoption. Despite these constraints, ongoing research, increasing focus on precision medicine, and the introduction of novel therapies are expected to create promising growth opportunities in the global myasthenia gravis therapeutics market.
Recent Developments
February 2026: Across North America, Europe, and Asia Pacific, rising prevalence of autoimmune disorders and increasing awareness of early diagnosis significantly boosted demand for myasthenia gravis therapeutics.
January 2026: Advancements in biologics such as FcRn inhibitors, complement inhibitors, and monoclonal antibodies enhanced treatment outcomes, enabling targeted and more effective disease management.
December 2025: Leading companies such as Johnson & Johnson, argenx, UCB Pharma, and AstraZeneca expanded therapeutic pipelines and strengthened their global market presence through innovation and strategic collaborations.
November 2025: Increasing adoption of subcutaneous and self-administered therapies enabled home-based treatment, improving patient convenience and reducing dependency on hospital-based care.
October 2025: Growing clinical pipeline, including gene therapies, immunotherapies, and next-generation biologics, accelerated innovation and expanded treatment options for patients.
September 2025: In the United States, strong investments in rare disease research, regulatory support, and increasing approvals accelerated market growth.
August 2025: In Japan, increasing focus on advanced biologics, aging population healthcare needs, and improved diagnostic capabilities supported market expansion.
July 2025: Rising adoption of immunosuppressants, intravenous immunoglobulin (IVIg), and emerging biologics highlighted the shift toward personalized and precision-based treatment approaches globally.
Market Companies and Competitive Landscape
The myasthenia gravis therapeutics market is moderately competitive with the presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Alexion Pharmaceutical Inc., Grifols SA, Avadel Pharmaceuticals plc. Novartis AG, Pfizer, Inc., AbbVie Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Bausch Health Companies Inc., and Shire plc. Alexion Pharmaceuticals and Astellas Pharma among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the myasthenia gravis therapeutics market globally.
Pfizer Inc.
Overview: Pfizer Inc. (Pfizer), incorporated on June 2, 1942, is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). IH focuses on developing and commercializing medicines and vaccines that improve patients' lives. IH therapeutic areas include internal medicine, vaccines, oncology, inflammation and immunology and rare diseases. EH includes legacy brands, branded generics, generic sterile injectable products, biosimilars and infusion systems. EH also includes a research and development (R&D) organization, as well as its contract manufacturing business. The Company sold its products in over 125 countries.
Product Portfolio: The Company’s portfolio comprised of include internal medicine, vaccines, oncology, inflammation and immunology and rare diseases and others.
